Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

All-cash deal could be worth up to $500 million in upfront and milestone payments.

You may also be interested in...



People In The News: Tracking The Latest Industry Personnel Moves

Former CMS Administrator Don Berwick joins think tank Center for American Progress as senior fellow. Elan announces the upcoming departure of CEO Kelly Martin. More personnel announcements in this month’s column.

Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?

Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.

Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?

Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel